Ann: Phylogica Strategic Update - Pivot to Platform, page-44

Now isn't this interesting...

Page 30 of the company's presentation dated 06/11/17 below, highlights that FPP efficiently targets cross presenting dendritic cells for an effective peptide vaccine, but what caught my attention was that both CD8 and CD4 T Cells were highlighted under "T Cell Activation and Expansion". However, the company only highlighted endosomal escaping CPPs will result in CD8+ T cell expansion via MHC I loading and FPP delivered antigen leads to greater expansion of CD8+ T cells compared to TAT. Was there any specific work conducted on CD4 T Cells?

http://phylogica.com/wp-content/uploads/2017/11/171106_Matrix-Datapack_BioEurope.pdf

Note, Dr Jason Waithman from the Telethon Kids Institute is the collaborator of this project.

https://www.telethonkids.org.au/contact-us/our-people/w/jason-waithman/

https://www.telethonkids.org.au/our...anoma-surveillance-by-tissue-resident-memory/

Whats now interesting is that this was all prior to the CD4 T Cells breakthrough discovery study published in December 2017 below.

https://www.sciencedaily.com/releases/2017/12/171220091745.htm

Will Phylogica also be turning their attention to CD4 T Cells as a result of this exciting development? Time will tell, but this is one project I'm keeping a very close eye on.

Remember the trial I posted a link to at the beginning of the month, CD8 and CD4 T Cells were the focus. Only a small trial, but very compelling.

http://www.cancertherapyadvisor.com...rial-yields-promising-results/article/679603/

Merry Christmas all.

Tony